Prelude Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-647
Closed -$212K 1198
2025
Q4
$212K Buy
+647
New +$205K 0.02% 1024
2025
Q1
Sell
-1,070
Closed -$279K 1172
2024
Q4
$279K Sell
1,070
-3,007
-74% -$892K 0.02% 831
2024
Q3
$1.31M Sell
4,077
-598
-13% -$196K 0.08% 314
2024
Q2
$1.46M Sell
4,675
-3,665
-44% -$1.08M 0.1% 243
2024
Q1
$2.37M Buy
+8,340
New +$2.44M 0.12% 202
2022
Q3
Sell
-1,230
Closed -$299K 1557
2022
Q2
$299K Buy
+1,230
New +$301K 0.01% 1061
2021
Q1
Sell
-2,744
Closed -$631K 1511
2020
Q4
$631K Buy
+2,744
New +$633K 0.02% 634
2020
Q1
Sell
-119
Closed -$29K 1403
2019
Q4
$29K Sell
119
-163
-58% -$35.9K ﹤0.01% 1504
2019
Q3
$55K Buy
+282
New +$54.1K ﹤0.01% 1132
2017
Q1
Sell
-4,358
Closed -$637K 1482
2016
Q4
$637K Buy
4,358
+2,633
+153% +$396K 0.08% 277
2016
Q3
$288K Sell
1,725
-319
-16% -$53.9K 0.03% 446
2016
Q2
$311K Sell
2,044
-415
-17% -$64.5K 0.04% 383
2016
Q1
$369K Sell
2,459
-4,012
-62% -$596K 0.05% 357
2015
Q4
$1.05M Buy
6,471
+1,191
+23% +$187K 0.16% 148
2015
Q3
$730K Buy
5,280
+237
+5% +$37.4K 0.11% 222
2015
Q2
$774K Buy
5,043
+1,313
+35% +$210K 0.11% 218
2015
Q1
$596K Sell
3,730
-1,773
-32% -$279K 0.08% 286
2014
Q4
$877K Buy
5,503
+2,224
+68% +$347K 0.13% 178
2014
Q3
$461K Buy
3,279
+735
+29% +$96K 0.06% 396
2014
Q2
$301K Sell
2,544
-4,970
-66% -$575K 0.04% 563
2014
Q1
$927K Buy
7,514
+1,069
+17% +$130K 0.12% 204
2013
Q4
$735K Buy
6,445
+3,950
+158% +$449K 0.12% 241
2013
Q3
$279K Sell
2,495
-3,643
-59% -$395K 0.05% 438
2013
Q2
$606K Buy
+6,138
New +$637K 0.13% 203

Other funds holding AMGN

Prelude Capital Management's AMGN Position: Q1 2026 in Review

Prelude Capital Management sold out of Amgen (AMGN) in Q1 2026, closing a stake of 647 shares — an estimated $212K sold.

Prelude Capital Management first reported a position in AMGN in Q2 2013 and held it in 24 quarters. The position peaked at $2.37M in Q1 2024. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Prelude Capital Management reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 647 Amgen shares in Q1 2026, an estimated $212K.
  • Prelude Capital Management first reported a position in Amgen in Q2 2013 and held it in 24 quarters.
  • Prelude Capital Management's Amgen position peaked at $2.37M in Q1 2024.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.